Exhaled Breath Condensate Biomarkers in CARAS

Henan University of Traditional Chinese Medicine

Status: Enrolling

Conditions: Combined Allergic Rhinitis and Asthma Syndrome

Treatments: Other: questionnaire survey

Study type: Observational

Funder types: Other

Identifiers

NCT06573450

EBC biomarkers in CARAS

Details and patient eligibility

About

To explore the differences in the expression of biomarkers in different sample types between the healthy population and different subgroups of the disease, and to screen for potential biomarkers in a more simple, direct and objective way. To screen the biomarkers that can be identified by CARAS Chinese medicine symptoms and different stages, and to provide a reference basis for individualised diagnosis and treatment of the disease.

Enrollment: 270 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patients with AR, BA and CARAS who meet the Western medical diagnostic criteria;
• Chinese medical evidence consistent with lung qi deficiency evidence, phlegm-heat congestion of the lung evidence, or wind-heat offending the lung evidence;
• Age 18 to 80 years;
• Voluntarily accepted the study and signed an informed consent form;
• Not participated in other clinical studies within 1 month before enrollment.

Exclusion criteria

• Patients with combined vasomotor rhinitis and eosinophilic non-allergic rhinitis, other non-allergic rhinitis diseases that can cause symptoms such as nasal congestion and runny nose;
• Patients who are participating in other drug trials;
• Patients with a combination of other serious systemic diseases;
• Pregnant or lactating women;
• Patients with confusion, disorders of consciousness, dementia, and various psychiatric disorders.

Trial design

270 participants in 9 patient groups

acute exacerbation CARAS

Description:

Thirty subjects were included. No intervention was performed and only relevant patient information, blood and exhaled breath condensate were collected.

Treatment:

Other: questionnaire survey

chronic persistence CARAS

Description:

Thirty subjects were included. No intervention was performed and only relevant patient information, blood and exhaled breath condensate were collected.

Treatment:

Other: questionnaire survey

clinical control CARAS

Description:

Thirty subjects were included. No intervention was performed and only relevant patient information, blood and exhaled breath condensate were collected.

Treatment:

Other: questionnaire survey

acute exacerbation BA

Description:

Thirty subjects were included. No intervention was performed and only relevant patient information, blood and exhaled breath condensate were collected.

Treatment:

Other: questionnaire survey

chronic persistence BA

Description:

Thirty subjects were included. No intervention was performed and only relevant patient information, blood and exhaled breath condensate were collected.

Treatment:

Other: questionnaire survey

clinical control BA

Description:

Thirty subjects were included. No intervention was performed and only relevant patient information, blood and exhaled breath condensate were collected.

Treatment:

Other: questionnaire survey

intermittent AR

Description:

Thirty subjects were included. No intervention was performed and only relevant patient information, blood and exhaled breath condensate were collected.

Treatment:

Other: questionnaire survey

persistent AR

Description:

Thirty subjects were included. No intervention was performed and only relevant patient information, blood and exhaled breath condensate were collected.

Treatment:

Other: questionnaire survey

healthy individuals

Description:

Thirty subjects were included. No intervention was performed and only relevant patient information, blood and exhaled breath condensate were collected.

Treatment:

Other: questionnaire survey